AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 6465150 — intervention group
Group type: COMPARATOR
Intervention: Decentralized unit dose system (control)
Number of subjects: 32
Study 30032545 — intervention group
Group type: EXPERIMENTAL
Intervention: Bivalirudin
Number of subjects: 74
Study 27680969 — intervention group
Group type: EXPERIMENTAL
Intervention: Diode laser (980 nm, 100 mW, 5.6 J/cm2, applied on days 0, 7, 14, 21, and 28 during canine retraction)
Number of subjects: 11
Study 27680969 — intervention group
Group type: COMPARATOR
Intervention: Control group (laser pseudo-application)
Number of subjects: 11
Study 27680969 — intervention group
Group type: EXPERIMENTAL
Intervention: Diode laser (980 nm)
Number of subjects: 11
Study 24813374 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-acting dexmethylphenidate (D-MPH) at doses of 10-20 mg
Number of subjects: 56
Study 24813374 — intervention group
Group type: EXPERIMENTAL
Intervention: Mixed amphetamine salts (MAS) at doses of 10-20 mg
Number of subjects: 56
Study 24813374 — intervention group
Group type: COMPARATOR
Intervention: Long-acting dexmethylphenidate (D-MPH) and Mixed amphetamine salts (MAS)
Number of subjects: 56
Study 23123106 — intervention group
Group type: EXPERIMENTAL
Intervention: AH-adjuvanted PcpA (25 μg)
Number of subjects: 131
Study 23123106 — intervention group
Group type: EXPERIMENTAL
Intervention: AH-adjuvanted PhtD-PcpA (10, 25, or 50 μg each)
Number of subjects: 131
Study 23123106 — intervention group
Group type: EXPERIMENTAL
Intervention: Unadjuvanted PhtD-PcpA (25 μg each)
Number of subjects: 131
Study 23123106 — intervention group
Group type: EXPERIMENTAL
Intervention: AH-adjuvanted vaccines
Number of subjects: 131
Study 23123106 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 131
Study 20124925 — intervention group
Group type: EXPERIMENTAL
Intervention: Distribution templates of fiducial points
Number of subjects: 85
Study 20124925 — intervention group
Group type: COMPARATOR
Intervention: Real fiducial points
Number of subjects: 85
Study 19195328 — intervention group
Group type: EXPERIMENTAL
Intervention: pegylated interferon‐alpha2b for 8 weeks
Number of subjects: 47
Study 19195328 — intervention group
Group type: EXPERIMENTAL
Intervention: lamivudine plus pegylated interferon‐alpha2b combination therapy for 24 weeks
Number of subjects: 47
Study 19195328 — intervention group
Group type: EXPERIMENTAL
Intervention: lamivudine monotherapy for 28 weeks
Number of subjects: 47
Study 15787659 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin lispro mixture plus metformin
Number of subjects: 97
Study 15787659 — intervention group
Group type: COMPARATOR
Intervention: Glargine plus metformin
Number of subjects: 97
Study 12453070 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2 g/kg IVIG
Number of subjects: 49
Study 12453070 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.4 g/kg IVIG
Number of subjects: 49
Study 12453070 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 49
Study 10404574 — intervention group
Group type: EXPERIMENTAL
Intervention: Paraspinal muscle fatigue (induced by upper trunk repetitive extensions against resistance until exhaustion)
Number of subjects: 106
Study 10404574 — intervention group
Group type: COMPARATOR
Intervention: No intervention (control group)
Number of subjects: 106
Study 7560627 — intervention group
Group type: EXPERIMENTAL
Intervention: Low intensity exercise training (40% of peak oxygen uptake) three times/week for 8 weeks
Number of subjects: 27
Study 2248072 — intervention group
Group type: EXPERIMENTAL
Intervention: Moclobemide (300 to 328 mg in first study; 294-408 mg in second study)
Number of subjects: 44
Study 2248072 — intervention group
Group type: COMPARATOR
Intervention: Amitriptyline (75 to 96 mg in first study; 95-129 mg in second study)
Number of subjects: 44
Study 7364977 — intervention group
Group type: EXPERIMENTAL
Intervention: Corticosteroid antimicrobial cream with fluocinonide 0.05%
Number of subjects: 88
Study 7364977 — intervention group
Group type: EXPERIMENTAL
Intervention: Corticosteroid antimicrobial cream with triamcinolone 0.1%
Number of subjects: 88
Study 7364977 — intervention group
Group type: COMPARATOR
Intervention: Cream containing only antimicrobial agents
Number of subjects: 88
Study 31835476 — intervention group
Group type: EXPERIMENTAL
Intervention: Fibre-enriched orange juice (1.4 g/100 mL of citrus fibre)
Number of subjects: 10
Study 31835476 — intervention group
Group type: COMPARATOR
Intervention: Placebo (regular orange juice without added fibre)
Number of subjects: 10
Study 29856685 — intervention group
Group type: EXPERIMENTAL
Intervention: ibrutinib plus rituximab
Number of subjects: 150
Study 29856685 — intervention group
Group type: COMPARATOR
Intervention: placebo plus rituximab
Number of subjects: 150
Study 26163858 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient education with exercise therapy
Number of subjects: 121
Study 26163858 — intervention group
Group type: COMPARATOR
Intervention: Patient education without exercise therapy
Number of subjects: 121
Study 24170391 — intervention group
Group type: EXPERIMENTAL
Intervention: Novel dog
Number of subjects: 48
Study 24170391 — intervention group
Group type: EXPERIMENTAL
Intervention: Human friend
Number of subjects: 48
Study 24170391 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 48
Study 22192348 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical management
Number of subjects: 652
Study 22192348 — intervention group
Group type: EXPERIMENTAL
Intervention: Outpatient manual vacuum aspiration (MVA)
Number of subjects: 652
Study 22192348 — intervention group
Group type: EXPERIMENTAL
Intervention: Inpatient electric vacuum aspiration (EVA)
Number of subjects: 652
Study 22192348 — intervention group
Group type: COMPARATOR
Intervention: Medical management
Number of subjects: 652
Study 19074911 — intervention group
Group type: EXPERIMENTAL
Intervention: Abatacept (approximately 10 mg/kg)
Number of subjects: 1046
Study 17867511 — intervention group
Group type: EXPERIMENTAL
Intervention: Multifocal intraocular lens Array (AMO)
Number of subjects: 30
Study 17867511 — intervention group
Group type: COMPARATOR
Intervention: Monofocal intraocular lens AcrySof (Alcon)
Number of subjects: 30
Study 15876443 — intervention group
Group type: EXPERIMENTAL
Intervention: Chloroquine (CQ)
Number of subjects: 619
Study 15876443 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulfadoxine-pyrimethamine (SP) in Caala
Number of subjects: 619
Study 15876443 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulfadoxine-pyrimethamine (SP) in Kuito
Number of subjects: 619
Study 15876443 — intervention group
Group type: EXPERIMENTAL
Intervention: Amodiaquine (AQ) in Caala
Number of subjects: 619
Study 15876443 — intervention group
Group type: EXPERIMENTAL
Intervention: Amodiaquine (AQ) in Kuito
Number of subjects: 619
Study 15876443 — intervention group
Group type: EXPERIMENTAL
Intervention: Amodiaquine + Artesunate (AQ+AS)
Number of subjects: 619
Study 15876443 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulfadoxine-pyrimethamine + Artesunate (SP+AS)
Number of subjects: 619
Study 11723014 — intervention group
Group type: EXPERIMENTAL
Intervention: Complete ST resolution (>/=70%)
Number of subjects: 13100
Study 11723014 — intervention group
Group type: EXPERIMENTAL
Intervention: Partial ST resolution (30% to 70%)
Number of subjects: 13100
Study 11723014 — intervention group
Group type: EXPERIMENTAL
Intervention: No ST resolution (<30%)
Number of subjects: 13100
Study 11723014 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients treated <2 hours after symptom onset
Number of subjects: 13100
Study 11723014 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients treated between 2 to 4 hours after symptom onset
Number of subjects: 13100
Study 11723014 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients treated >4 hours after symptom onset
Number of subjects: 13100
Study 11723014 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients treated <2 hours with partial ST resolution
Number of subjects: 13100
Study 11723014 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients treated between 2 to 4 hours with partial ST resolution
Number of subjects: 13100
Study 11723014 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients treated >4 hours with partial ST resolution
Number of subjects: 13100
Study 11723014 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients treated <2 hours with no ST resolution
Number of subjects: 13100
Study 11723014 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients treated between 2 to 4 hours with no ST resolution
Number of subjects: 13100
Study 11723014 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients treated >4 hours with no ST resolution
Number of subjects: 13100
Study 9190163 — intervention group
Group type: EXPERIMENTAL
Intervention: Intubation with thiopental and vecuronium bromide
Number of subjects: 200
Study 9190163 — intervention group
Group type: EXPERIMENTAL
Intervention: Laryngeal mask (LMN) with thiopental
Number of subjects: 200
Study 9190163 — intervention group
Group type: EXPERIMENTAL
Intervention: Laryngeal mask (LMN) with propofol
Number of subjects: 200
Study 9190163 — intervention group
Group type: COMPARATOR
Intervention: Routine LMN control group (100 children)
Number of subjects: 200
Study 7965897 — intervention group
Group type: EXPERIMENTAL
Intervention: All‐Bond‐2 adhesive
Number of subjects: 45
Study 7965897 — intervention group
Group type: EXPERIMENTAL
Intervention: Amalgambond Plus adhesive
Number of subjects: 45
Study 7965897 — intervention group
Group type: EXPERIMENTAL
Intervention: TMS Minim pins
Number of subjects: 45
Study 3294615 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefamandole (15 mg/kg)
Number of subjects: 10
Study 3294615 — intervention group
Group type: EXPERIMENTAL
Intervention: Tobramycin (1.5 mg/kg)
Number of subjects: 10
Study 3294615 — intervention group
Group type: EXPERIMENTAL
Intervention: Tobramycin (3 mg/kg)
Number of subjects: 10
Study 3294615 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefamandole (15 mg/kg) + Tobramycin (1.5 mg/kg)
Number of subjects: 10
Study 3294615 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefamandole (15 mg/kg) + Tobramycin (3 mg/kg)
Number of subjects: 10
Study 3294615 — intervention group
Group type: COMPARATOR
Intervention: Cefamandole alone
Number of subjects: 10
Study 30431426 — intervention group
Group type: EXPERIMENTAL
Intervention: FS Spiromax 500/50 µg
Number of subjects: 156
Study 30431426 — intervention group
Group type: COMPARATOR
Intervention: Seretide Accuhaler 50/500 µg
Number of subjects: 156
Study 30431426 — intervention group
Group type: EXPERIMENTAL
Intervention: FS Spiromax 500/50 µg with charcoal block
Number of subjects: 156
Study 30431426 — intervention group
Group type: COMPARATOR
Intervention: Seretide Accuhaler 50/500 µg with charcoal block
Number of subjects: 156
Study 30431426 — intervention group
Group type: EXPERIMENTAL
Intervention: FS Spiromax and Seretide Accuhaler
Number of subjects: 156
Study 30431426 — intervention group
Group type: EXPERIMENTAL
Intervention: FS Spiromax
Number of subjects: 156
Study 30431426 — intervention group
Group type: COMPARATOR
Intervention: Seretide Accuhaler
Number of subjects: 156
Study 28453445 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Exercise Approach (CBEA)
Number of subjects: 41
Study 28453445 — intervention group
Group type: COMPARATOR
Intervention: Usual Care
Number of subjects: 41
Study 25884190 — intervention group
Group type: EXPERIMENTAL
Intervention: e-learning program and a brochure
Number of subjects: 322
Study 25884190 — intervention group
Group type: COMPARATOR
Intervention: brochure only
Number of subjects: 322
Study 24080020 — intervention group
Group type: EXPERIMENTAL
Intervention: CRA plus CM
Number of subjects: 108
Study 24080020 — intervention group
Group type: COMPARATOR
Intervention: CRA
Number of subjects: 108
Study 24080020 — intervention group
Group type: EXPERIMENTAL
Intervention: CM
Number of subjects: 108
Study 24080020 — intervention group
Group type: EXPERIMENTAL
Intervention: Interaction of unemployment and depressive symptoms
Number of subjects: 108
Study 21819934 — intervention group
Group type: EXPERIMENTAL
Intervention: Decompensated LC
Number of subjects: 25
Study 21819934 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 25
Study 21819934 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with TIPS
Number of subjects: 25
Study 19175713 — intervention group
Group type: EXPERIMENTAL
Intervention: Alpha lipoic acid (ALA)
Number of subjects: 38
Study 19175713 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38
Study 16720619 — intervention group
Group type: EXPERIMENTAL
Intervention: Dr Atkins' new diet revolution
Number of subjects: 0
Study 16720619 — intervention group
Group type: EXPERIMENTAL
Intervention: Slim‐Fast plan
Number of subjects: 0
Study 16720619 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight Watchers pure points programme
Number of subjects: 0
Study 16720619 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosemary Conley's eat yourself slim diet and fitness plan
Number of subjects: 0
Study 16720619 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 14699543 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous antibiotics
Number of subjects: 56
Study 14699543 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intravenous antibiotics)
Number of subjects: 56
Study 11721154 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard calcium reduced diet (300 mg/24 h) for 4 weeks after a 3-week run-in period (dietary calcium content 700-1,000 mg/24 h)
Number of subjects: 27
Study 11721154 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal calcium-containing diet after the calcium restriction period
Number of subjects: 27
Study 11721154 — intervention group
Group type: COMPARATOR
Intervention: Control group (43 healthy persons)
Number of subjects: 27
Study 9012545 — intervention group
Group type: EXPERIMENTAL
Intervention: Sizofiran (SPG) administration
Number of subjects: 0
Study 1376812 — intervention group
Group type: EXPERIMENTAL
Intervention: Lisinopril 20 mg
Number of subjects: 24
Study 1376812 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 3891497 — intervention group
Group type: EXPERIMENTAL
Intervention: Heidelberg capsule after a 4-ml/kg liquid fatty meal
Number of subjects: 22
Study 3891497 — intervention group
Group type: EXPERIMENTAL
Intervention: Frequent feeding
Number of subjects: 22
Study 3891497 — intervention group
Group type: EXPERIMENTAL
Intervention: Liquid meal (200 ml of diluted light cream)
Number of subjects: 22
Study 3891497 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard breakfast including solid food
Number of subjects: 22
Study 31704939 — intervention group
Group type: EXPERIMENTAL
Intervention: Batch email interruptions with exogenous stress
Number of subjects: 63
Study 31704939 — intervention group
Group type: COMPARATOR
Intervention: Batch email interruptions without exogenous stress
Number of subjects: 63
Study 31704939 — intervention group
Group type: EXPERIMENTAL
Intervention: Continual email interruptions with exogenous stress
Number of subjects: 63
Study 31704939 — intervention group
Group type: COMPARATOR
Intervention: Continual email interruptions without exogenous stress
Number of subjects: 63
Study 30269275 — intervention group
Group type: EXPERIMENTAL
Intervention: ABP 215
Number of subjects: 24
Study 30269275 — intervention group
Group type: COMPARATOR
Intervention: Bevacizumab
Number of subjects: 24
Study 27421057 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination HIV prevention package (including household‐based HIV counselling and testing and anti‐retroviral treatment eligibility regardless of CD4‐count)
Number of subjects: 21
Study 27421057 — intervention group
Group type: EXPERIMENTAL
Intervention: Broad Brush Survey (BBS) qualitative data
Number of subjects: 21
Study 27421057 — intervention group
Group type: EXPERIMENTAL
Intervention: Meta-indicators of local context
Number of subjects: 21
Study 24645793 — intervention group
Group type: EXPERIMENTAL
Intervention: Avenanthramide (AVA) supplementation (9.2 mg AVA per day)
Number of subjects: 16
Study 24645793 — intervention group
Group type: COMPARATOR
Intervention: Control (0.4 mg AVA per day)
Number of subjects: 16
Study 23235391 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose erythropoietin stimulating agent (ESA) treatment
Number of subjects: 0
Study 23235391 — intervention group
Group type: COMPARATOR
Intervention: No erythropoietin stimulating agent (no-ESA) treatment
Number of subjects: 0
Study 19896252 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactobacillus GG (LGG) at a dose of 10^9 colony-forming units in 100ml of a fermented milk product
Number of subjects: 281
Study 19896252 — intervention group
Group type: COMPARATOR
Intervention: Placebo (same post-pasteurized fermented milk product without LGG)
Number of subjects: 281
Study 17828687 — intervention group
Group type: EXPERIMENTAL
Intervention: Multimodal intervention program
Number of subjects: 404
Study 17828687 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 404
Study 15994629 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture treatment
Number of subjects: 85
Study 15994629 — intervention group
Group type: COMPARATOR
Intervention: Placebo acupuncture treatment
Number of subjects: 85
Study 12435170 — intervention group
Group type: EXPERIMENTAL
Intervention: Darbepoetin alfa 3.0 microg/kg every 2 weeks
Number of subjects: 0
Study 12435170 — intervention group
Group type: EXPERIMENTAL
Intervention: Darbepoetin alfa 5.0 microg/kg every 2 weeks
Number of subjects: 0
Study 12435170 — intervention group
Group type: COMPARATOR
Intervention: Epoetin alfa 40,000 U weekly (increased to 60,000 U weekly for inadequate response)
Number of subjects: 0
Study 10342360 — intervention group
Group type: EXPERIMENTAL
Intervention: rhGH
Number of subjects: 7
Study 10342360 — intervention group
Group type: EXPERIMENTAL
Intervention: Hexarelin (HEX)
Number of subjects: 7
Study 8954380 — intervention group
Group type: EXPERIMENTAL
Intervention: Tai Chi Chih (60 minutes once a week for 10 weeks)
Number of subjects: 46
Study 8954380 — intervention group
Group type: COMPARATOR
Intervention: Control group (current level of activity)
Number of subjects: 46
Study 8250189 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoflurane
Number of subjects: 34
Study 8250189 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 34
Study 3562679 — intervention group
Group type: EXPERIMENTAL
Intervention: Written information with verbal reinforcement
Number of subjects: 150
Study 3562679 — intervention group
Group type: COMPARATOR
Intervention: Control group (no hand-out)
Number of subjects: 150
Study 30156436 — intervention group
Group type: EXPERIMENTAL
Intervention: MEC (DigeZyme®) 50 mg, TID for 60 days
Number of subjects: 40
Study 30156436 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 28160012 — intervention group
Group type: EXPERIMENTAL
Intervention: Seletalisib (5-90 mg QD and 30 mg BID)
Number of subjects: 0
Study 28160012 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 24057053 — intervention group
Group type: EXPERIMENTAL
Intervention: Auditory-fast condition (voluntarily stopped fast movement in response to auditory cue)
Number of subjects: 0
Study 24057053 — intervention group
Group type: EXPERIMENTAL
Intervention: Auditory-slow condition (voluntarily stopped slow movement in response to auditory cue)
Number of subjects: 0
Study 24057053 — intervention group
Group type: EXPERIMENTAL
Intervention: Obstacle conditions (mechanically prevented from moving further)
Number of subjects: 0
Study 21840468 — intervention group
Group type: EXPERIMENTAL
Intervention: Placebo plus mixture of hesperidin, luteolin, and naringenin
Number of subjects: 16
Study 21840468 — intervention group
Group type: EXPERIMENTAL
Intervention: Orange juice (positive control)
Number of subjects: 16
Study 21840468 — intervention group
Group type: COMPARATOR
Intervention: Placebo (ascorbic acid and sugar equivalent to orange juice)
Number of subjects: 16
Study 21840468 — intervention group
Group type: EXPERIMENTAL
Intervention: Placebo plus hesperidin
Number of subjects: 16
Study 19717722 — intervention group
Group type: EXPERIMENTAL
Intervention: Raltegravir 400 mg twice daily from days 1 to 5 with 100 mg lamotrigine on day 4
Number of subjects: 24
Study 19717722 — intervention group
Group type: COMPARATOR
Intervention: Lamotrigine 100 mg alone on day 32
Number of subjects: 24
Study 19717722 — intervention group
Group type: EXPERIMENTAL
Intervention: Raltegravir + lamotrigine
Number of subjects: 24
Study 19717722 — intervention group
Group type: COMPARATOR
Intervention: Lamotrigine alone
Number of subjects: 24
Study 17489013 — intervention group
Group type: EXPERIMENTAL
Intervention: Progressive resistance training (PRT) during shoulder press exercise
Number of subjects: 1
Study 14644147 — intervention group
Group type: EXPERIMENTAL
Intervention: Serial MRI analysis technique for cerebral atrophy
Number of subjects: 0
Study 14644147 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 11497195 — intervention group
Group type: EXPERIMENTAL
Intervention: Omapatrilat (10 or 20 mg, titrated to 20 or 40 mg) plus 25 mg of HCTZ
Number of subjects: 657
Study 11497195 — intervention group
Group type: EXPERIMENTAL
Intervention: Omapatrilat (20/40 mg) plus 25 mg of HCTZ
Number of subjects: 657
Study 11497195 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus 25 mg of HCTZ
Number of subjects: 657
Study 9032212 — intervention group
Group type: EXPERIMENTAL
Intervention: Platelet-derived growth factor (PDGF) positive cells in BOOP
Number of subjects: 30
Study 9032212 — intervention group
Group type: COMPARATOR
Intervention: Control subjects
Number of subjects: 30
Study 9032212 — intervention group
Group type: EXPERIMENTAL
Intervention: CD68+ macrophages in BOOP
Number of subjects: 30
Study 9032212 — intervention group
Group type: EXPERIMENTAL
Intervention: PDGFR-beta immunoreactivity in BOOP
Number of subjects: 30
Study 8345313 — intervention group
Group type: EXPERIMENTAL
Intervention: High-velocity, low-amplitude, short lever adjustment of a single vertebra from among C1 and T3-T7
Number of subjects: 42
Study 8345313 — intervention group
Group type: COMPARATOR
Intervention: Sham adjustment similar to a manual diagnostic pressure test at C1, T3-T7 or T9-T10
Number of subjects: 42
Study 2938394 — intervention group
Group type: EXPERIMENTAL
Intervention: Alfentanil (50 micrograms/kg) and atracurium (0.5 mg/kg)
Number of subjects: 62
Study 2938394 — intervention group
Group type: COMPARATOR
Intervention: Fentanyl (5 micrograms/kg) and pancuronium (0.07 mg/kg)
Number of subjects: 62
Study 31729771 — intervention group
Group type: EXPERIMENTAL
Intervention: Teamwork enhancement and quality improvement program
Number of subjects: 72
Study 29294363 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxytocin administration
Number of subjects: 285
Study 29294363 — intervention group
Group type: COMPARATOR
Intervention: No intervention (control group)
Number of subjects: 285